Research Analysts Set Expectations for KTTA Q1 Earnings

Pasithea Therapeutics Corp. (NASDAQ:KTTA) – Stock analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Pasithea Therapeutics in a research note issued on Tuesday, March 31st. HC Wainwright analyst S. Nik anticipates that the company will post earnings per share of ($0.45) for the quarter. HC Wainwright currently has a “Buy” rating and a $3.00 price target on the stock. HC Wainwright also issued estimates for Pasithea Therapeutics’ Q2 2026 earnings at ($0.45) EPS, Q3 2026 earnings at $0.48 EPS and Q4 2026 earnings at $0.48 EPS.

A number of other research firms have also weighed in on KTTA. Wall Street Zen upgraded shares of Pasithea Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, January 18th. Zacks Research upgraded shares of Pasithea Therapeutics to a “hold” rating in a research report on Tuesday, December 9th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Pasithea Therapeutics in a research note on Friday, March 27th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Pasithea Therapeutics has an average rating of “Hold” and a consensus target price of $3.00.

Pasithea Therapeutics Trading Up 0.3%

NASDAQ:KTTA opened at $0.74 on Thursday. Pasithea Therapeutics has a 12-month low of $0.28 and a 12-month high of $3.79. The stock’s 50 day simple moving average is $0.80 and its 200-day simple moving average is $0.85. The firm has a market cap of $18.56 million, a P/E ratio of -0.21 and a beta of 0.25.

Pasithea Therapeutics (NASDAQ:KTTA) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.71).

Hedge Funds Weigh In On Pasithea Therapeutics

A number of large investors have recently made changes to their positions in the stock. Two Sigma Investments LP purchased a new stake in Pasithea Therapeutics during the third quarter worth about $26,000. Citadel Advisors LLC raised its holdings in Pasithea Therapeutics by 43.7% during the third quarter. Citadel Advisors LLC now owns 67,341 shares of the company’s stock worth $48,000 after purchasing an additional 20,483 shares during the last quarter. Geode Capital Management LLC boosted its position in Pasithea Therapeutics by 113.9% during the fourth quarter. Geode Capital Management LLC now owns 54,495 shares of the company’s stock worth $70,000 after purchasing an additional 29,020 shares in the last quarter. Jane Street Group LLC boosted its position in Pasithea Therapeutics by 137.0% during the fourth quarter. Jane Street Group LLC now owns 59,372 shares of the company’s stock worth $77,000 after purchasing an additional 34,319 shares in the last quarter. Finally, AdvisorShares Investments LLC grew its holdings in Pasithea Therapeutics by 33.1% in the third quarter. AdvisorShares Investments LLC now owns 257,696 shares of the company’s stock valued at $186,000 after purchasing an additional 64,149 shares during the last quarter. Hedge funds and other institutional investors own 23.92% of the company’s stock.

About Pasithea Therapeutics

Pasithea Therapeutics, Inc (NASDAQ: KTTA) is a clinical?stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways.

The company’s pipeline consists of multiple preclinical and early clinical candidates targeting autoimmune and inflammatory disorders.